Evicenter
P&T meetings

4D-150

Neovascular age-related macular degeneration

Regulatory submission
Not announced
Launch
Not announced
Last updated
180 sources

Product information and disease descriptionProduct descriptionProduct information

Generic, brand name and therapeutic class of product

2 evidence topics · 4 sources

Manufacturer: 4D Molecular Therapeutics

“ClinicalTrials.gov ID NCT06864988 Sponsor 4D Molecular Therapeutics Information provided by 4D Molecular Therapeutics (Responsible Party)” (opens the source at this quote in a new tab)

“4DMT retains full development and commercialization rights for 4D-150 outside the APAC region, including the U.S., Latin America and Europe.” (opens the source at this quote in a new tab)

Nonproprietary name, brand name, and code name

No evidence found.

Therapeutic class: intravitreal AAV gene therapy expressing anti-VEGF biologics

“4D-150 utilizes our customized and evolved intravitreal AAV vector, R100, which was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform.” (opens the source at this quote in a new tab)

“Our lead product candidate 4D-150 utilizes our proprietary R100 vector and a transgene encoding anti-VEGF biologics: aflibercept and an RNA interference (RNAi) approach targeting VEGF-C.” (opens the source at this quote in a new tab)